-
Innovation Ranking
NewInnovation Ranking – Beam Therapeutics Inc
Beam Therapeutics Inc (Beam Therapeutics) is a biotechnology company. The company develops precision genetic medicines to treat serious genetic diseases. It is investigating BEAM-101 targeting sickle cell disease and beta-thalassemia, BEAM-102 against sickle cell disease and BEAM-201 for the treatment of T-cell acute lymphoblastic leukemia. Beam Therapeutics is also evaluating therapies against acute myeloid leukemia, alpha 1 antitrypsin deficiency, glycogen storage disorder 1a and Stargardt disease. It utilizes the REPAIR system for A-to-I (adenosine to inosine) RNA (Ribonucleic acid) editing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BEAM-101 in Beta Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BEAM-101 in Beta Thalassaemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BEAM-101 in Beta Thalassaemia Drug Details: BEAM-101 is under development for the...
-
Product Insights
NewNet Present Value Model: Beam Therapeutics Inc’s BEAM-101
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Net Present Value Model: Beam Therapeutics Inc’s BEAM-201
Empower your strategies with our Net Present Value Model: Beam Therapeutics Inc's BEAM-201 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Beam Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Beam Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Ion Beam Applications SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Ion Beam Applications SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
CRRCNP/ Mota-Engil – Marin Prefabricated Straight Beams Production Plant – Nuevo Leon
Equip yourself with the essential tools needed to make informed and profitable decisions with our CRRCNP/ Mota-Engil – Marin Prefabricated Straight Beams Production Plant – Nuevo Leon report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BEAM-101 in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BEAM-101 in Sickle Cell Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BEAM-101 in Sickle Cell Disease Drug Details:BEAM-101 is under development for the...
-
Track & Monitor
Innovation in automotive: Vehicle headlight beam contours
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the automotive industry’s Vehicle headlight beam contours segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Thematic Analysis
NewRNA-Based Drugs and the Impact of COVID-19
This report investigates the past, current and future landscape of RNA-Based drugs, and how the success of the COVID-19 vaccines may have impacted this. High level analysis of the key trends and movements within the pharmaceutical industry in reference to RNA technology is provided, allowing you to identify and discern the key points within this area.